Fasenra (benralizumab) is a monoclonal antibody that helps the body’s immune system by reducing the level of a certain type of white blood cells helping to protect healthy cells from damage. Specifically it is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody (IgG1 kappa) used as an add-on maintenance treatment of patients with severe asthma aged 12 years and older with an eosinophilic phenotype.
For more information, visit the patient website for this drug. Speak with your healthcare provider to learn if this drug is right for you.
Biologics (IL-5 monoclonal antibodies)
WHAT IT TREATS:
Severe Eosinophilic Asthma
Every 4 weeks for 3 doses then every 8 weeks
Length of infusion:
About 15 minutes plus 30 minutes observation
FOR MORE INFORMATION: